GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blum Holdings Inc (OTCPK:BLMH) » Definitions » Gross Profit

Blum Holdings (Blum Holdings) Gross Profit : $15.52 Mil (TTM As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Blum Holdings Gross Profit?

Blum Holdings's gross profit for the three months ended in Sep. 2023 was $3.99 Mil. Blum Holdings's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $15.52 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Blum Holdings's gross profit for the three months ended in Sep. 2023 was $3.99 Mil. Blum Holdings's Revenue for the three months ended in Sep. 2023 was $8.61 Mil. Therefore, Blum Holdings's Gross Margin % for the quarter that ended in Sep. 2023 was 46.38%.

Blum Holdings had a gross margin of 46.38% for the quarter that ended in Sep. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Blum Holdings was 62.77%. The lowest was 2.16%. And the median was 28.33%.

Warning Sign:

Blum Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -2.6%.


Blum Holdings Gross Profit Historical Data

The historical data trend for Blum Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blum Holdings Gross Profit Chart

Blum Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.01 10.35 2.64 11.02 16.90

Blum Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 2.74 4.18 4.60 3.99

Competitive Comparison of Blum Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Blum Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blum Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blum Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Blum Holdings's Gross Profit falls into.



Blum Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Blum Holdings's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=52.015 - 35.118
=16.90

Blum Holdings's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=8.612 - 4.618
=3.99

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.52 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Blum Holdings's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=3.99 / 8.612
=46.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Blum Holdings  (OTCPK:BLMH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Blum Holdings had a gross margin of 46.38% for the quarter that ended in Sep. 2023 => Durable competitive advantage


Blum Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Blum Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Blum Holdings (Blum Holdings) Business Description

Traded in Other Exchanges
N/A
Address
3242 South Halladay Street, Suite 202, Santa Ana, CA, USA, 92705
Blum Holdings Inc formerly Unrivaled Brands Inc is a vertically integrated cannabis multi-state operator having a cannabis brand spanning consumer products, cultivation, distribution, and retail. Its brands include Korova, Sticks, and Cabana, among others. It operates leading dispensaries throughout the state as well as several leading company-owned brands including Korova, known for its high potency products across multiple product categories.
Executives
Patty Chan officer: CHIEF FINANCIAL OFFICER 11516 DOWNEY AVE, DOWNEY CA 90241
Oren Schauble officer: President 3242 S HALLADAY ST., SUITE 202, SANTA ANA CA 92705
Dallas Imbimbo director 1800 NEWPORT CIRCLE, SANTA ANA CA 92705
Eric Baum director 866 BERKSHIRE DRIVE, WESTBURY NY 11590
Tiffany N. Davis director 11852 MANHATTAN CT., RANCHO CUCAMONGA CA 91730
Michael Nahass director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Derek Peterson director, officer: President and CEO 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Alan David Gladstone other: Former Director of Issuer P.O BOX 9699, NEWPORT BEACH CA 92658
Uri Kenig officer: Chief Operating Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Ira E. Ritter director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Nicholas Kovacevich director 2618 SAN MIGUEL DRIVE, #480, NEWPORT BEACH CA 92660
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Jeffrey Robert Batliner officer: Chief Financial Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Megan Jimenez officer: Chief Financial Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Matthew Morgan director, officer: Chief Executive Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614